Comparison of the survivor and non-survivor groups
A comparison of the survivor and non-survivor groups is presented in Tables 1 and 2. The prevalence of chronic heart failure (CHF) and history of malignancy was significantly higher in the non-survivor group than in the survivor group (p = 0.033 and p < 0.001, respectively). The mean GNRI score was significantly lower in the non-survivor group than in the survivor group (p < 0.001), with 72 (74.2%) patients identified as having severe nutrition risk (GNRI <82). Serum BUN and albumin levels were significantly lower and the A-DROP score was significantly higher in the non-survivor group than in the survivor group (BUN: p = 0.039, albumin: p < 0.001, A-DROP: p < 0.001). ABPC/SBT was more frequently administered as an initial treatment regimen in the survivor group than in the non-survivor group (p = 0.044). The frequency of first-choice PIPC/TAZ exhibited a trend to be lower in the survival group than in the non-survival group (survivor vs. non-survivor: 8.2% vs. 14.4%), but this did not reach significance (p = 0.056). The frequency of initial antibiotic change was significantly higher in the non-survivor group than in the survivor group (p < 0.001). No significant between-group difference was observed in the isolation rate of specific pathogens, including PDR pathogens (Table 2).